Drug Profile
Research programme: melioidosis therapeutics - Precigen Inc/Soligenix
Alternative Names: SGX 101Latest Information Update: 10 Feb 2020
Price :
$50
*
At a glance
- Originator Intrexon Corporation; Soligenix
- Developer Precigen Inc; Soligenix
- Class Monoclonal antibodies; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Melioidosis
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Sep 2018 No recent reports of development identified for preclinical development in Melioidosis in USA (Parenteral)
- 19 Aug 2014 Preclinical trials in Melioidosis in USA (Parenteral)